Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
|Articles|September 1, 2022
Daily Medication Pearl: Bupivacaine and Meloxicam (Zynrelef)
Author(s)Saro Arakelians, PharmD
Zynrelef is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.
Advertisement
Medication Pearl of the Day: Bupivacaine and Meloxicam (Zynrelef)
Indication: Zynrelef contains bupivacaine, an amide local anesthetic, and meloxicam, a nonsteroidal anti-inflammatory drug (NSAID). It is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.
Insight:
- Dosing: The recommended dose of Zynrelef is up to a maximum dose of 400 mg/12 mg (14 mL).
- Dosage forms: Zynrelef extended-release solution is available in 4 dosage strengths as single-dose glass vials—400 mg bupivacaine and 12 mg meloxicam; 300 mg bupivacaine and 9 mg meloxicam; 200 mg bupivacaine and 6 mg meloxicam; 60 mg bupivacaine and 1.8 mg meloxicam.
- Adverse events: Most common adverse reactions (incidence ≥10%) are constipation, vomiting, and headache.
- Mechanism of action: Local anesthetics block the generation and the conduction of nerve impulses presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Meloxicam is a potent inhibitor of prostaglandin synthesis in vitro. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models.
Advertisement
Related to this article
Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Most patients screened by a hospital pharmacist-led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.
The FDA has approved rebisufligene etisparvovec-hopf (Fayuvi), the first treatment designed to alter the course of mucopolysaccharidosis type IIIA.
A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
5